Novartis gene therapy approved, but will come at cost of more than $2 million
A gene therapy approved by the FDA offers a potential one-time fix for a rare genetic condition known as spinal muscular atrophy that is fatal to young children.
Novartis’ Zolgensma is only the second gene therapy for an inherited disorder to be cleared for commercial use in the U.S. However, the therapy is also notable for its price. At $2.125M per dose, Zolgensma is the most expensive treatment ever brought to market. Novartis intends for that price to be paid in installments of $425,000 a year for five years.